Sernova (TSE:SVA) Shares Down 18.5% – What’s Next?

Sernova Corp. (TSE:SVA)’s stock price traded down 18.5% during trading on Monday . The stock traded as low as C$0.11 and last traded at C$0.11. Approximately 674,159 shares were traded during trading, an increase of 415% from the average session volume of 130,839 shares. The stock had previously closed at C$0.14.

Sernova Stock Down 9.1%

The stock has a market capitalization of C$37.76 million, a PE ratio of -2.50 and a beta of -0.43. The firm has a 50 day moving average of C$0.11 and a two-hundred day moving average of C$0.14. The company has a current ratio of 0.03, a quick ratio of 18.11 and a debt-to-equity ratio of -21.98.

Sernova (TSE:SVA) last posted its earnings results on Thursday, September 10th. The company reported C($0.01) EPS for the quarter. Equities research analysts anticipate that Sernova Corp. will post -0.08 earnings per share for the current year.

Sernova Company Profile

Sernova Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem-cell derived islet-like clusters in collaboration with Evotec to create bio-hybrid organs to treat T1D. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This innovative approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on T1D and thyroid disorders.